- Home
- PRE
as 07-05-2024 1:37pm EST
Prenetics Global Ltd is a genomics-driven health sciences company, that is revolutionizing prevention, early detection, and treatment. The company's prevention arm, CircleDNA, uses whole exome sequencing to offer comprehensive consumer DNA tests. Insighta, Its joint venture with scientist Prof. Dennis Lo, underscores the company's unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, its treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances its global impact on health, truly embodying Prenetics commitment to 'enhancing life through science'.
| Founded: | 2014 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 72.3M | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 46.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.85 - $13.59 | Next Earning Date: | 06-18-2024 |
| Revenue: | $10,607,556 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1436.84% | Revenue Growth (next year): | -52.66% |
Latest Prenetics Global Limited News
PRE Breaking Stock News: Dive into PRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors
Simply Wall St.
5 days ago
We Think Prenetics Global (NASDAQ:PRE) Can Afford To Drive Business Growth
GlobeNewswire
17 days ago
Prenetics Announces First Quarter 2024 Financial Results
GlobeNewswire
18 days ago
Prenetics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
PR Newswire
3 months ago
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results
PR Newswire
5 months ago
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
PR Newswire
5 months ago
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Yahoo Finance Video
5 months ago
Stocks open lower, Big Tech earnings on deck
Share on Social Networks:
Disclaimer
The information presented on this page, "PRE Prenetics Global Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.